Edition:
United Kingdom

People: Pacific Biosciences of California Inc (PACB.OQ)

PACB.OQ on NASDAQ Stock Exchange Global Select Market

5.33USD
19 Jul 2019
Change (% chg)

$-0.55 (-9.35%)
Prev Close
$5.88
Open
$5.84
Day's High
$5.84
Day's Low
$5.04
Volume
1,642,805
Avg. Vol
381,904
52-wk High
$7.84
52-wk Low
$3.33

Ordonez, Kathy 

Ms. Kathy P. Ordonez is Director of Pacific Biosciences of California Inc. Ms. Ordoñez has been a member of our Board of Directors since December 2014. She served as our Chief Commercial Officer and Executive Vice President from October 2017 to October 2018. Ms. Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. From January 2012 until June 2013, Ms. Ordoñez was a Senior Vice President at Quest Diagnostics Incorporated, a leading provider of diagnostic information services, where she was initially responsible for leading their R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. Ms. Ordoñez joined Quest Diagnostics as part of its acquisition in 2011 of Celera Corporation, a leading provider of genetic testing products for HIV resistance, cystic fibrosis and high complexity tissue transplantation. From April 2002 until May 2011, Ms. Ordoñez was the Chief Executive Officer at Celera, and she founded Celera Diagnostics in December 2000. From 1985 until 2000, Ms. Ordoñez held several senior positions at Hoffmann-La Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields. Ms. Ordoñez also served as Director, non-executive Chairman, and Chief Executive Officer of RainDance Technologies, Inc., which was sold to Bio-Rad Laboratories, Inc. in February 2017. We believe that Ms. Ordoñez possesses specific attributes that qualify her to serve as a member of our Board of Directors, including her extensive experience in the life sciences and diagnostic industries.

Basic Compensation

Total Annual Compensation, USD 170,001
Restricted Stock Award, USD 373,953
Long-Term Incentive Plans, USD --
All Other, USD 141,804
Fiscal Year Total, USD 685,758

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Hunkapiller

1,610,870

Susan Barnes

1,125,760

James Phillips

616,991

William Ericson

106,405

Kathy Ordonez

685,758

David Botstein

77,405
As Of  31 Dec 2018